VANFLYTA Tablet Post-marketing Surveillance Study
Not Applicable
Completed
- Conditions
- Relapsed or refractory acute myeloid leukemia with FLT3-ITD mutation positive
- Registration Number
- jRCT1080224910
- Lead Sponsor
- DAIICHI SANKYO CO., LTD.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- All
- Target Recruitment
- 210
Inclusion Criteria
All patients who start receiving VANFLYTA Tablet during the registration period.
Exclusion Criteria
Patients with a previous history of hypersensitivity to the ingredients of VANFLYTA.
Study & Design
- Study Type
- Observational
- Study Design
- Observational surveillance (Post-marketing surveillance)
- Primary Outcome Measures
Name Time Method safety Information about the adverse events that have occurred, by adverse reaction/infection category.
Information about the safety specifications concerns that have occurred.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Japan
Location not specified
Japan